VolitionRX Ltd
VolitionRX Ltd is a biotechnology company focused on developing blood tests for cancer and other diseases using its biomarker platform called Nu.Q.
Price history of VolitionRX Ltd
Price history of VolitionRX Ltd
Performance & Momentum
Strategic Analysis
VolitionRX Ltd • 2026
VolitionRX Ltd positions itself as a specialist in non-invasive molecular diagnostics, with an offering centered on blood-based tests using Nu.Q technology for the detection and monitoring of certain diseases, notably in oncology. Its value proposition rests on differentiated biomarkers and the ambition to make screening simpler and more accessible than traditional diagnostic approaches.
- Niche positioning in biomarkers and blood-based oncology testing
- Proprietary Nu.Q technology, potentially differentiated in molecular diagnostics
- Exposure to a structurally attractive healthcare market centered on cancer screening and monitoring
- Very poor share price history, reflecting strong market skepticism
- Dependence on the clinical, regulatory, and commercial success of its tests
- Small-cap biotech profile generally exposed to dilution and limited financial visibility
Momentum is very weak and reflects a persistent downtrend across multiple timeframes, with no visible sign of a reversal. In the absence of recent news, the investment case remains highly speculative: tangible progress in clinical validation, commercial adoption, or partnerships will be needed to restore credibility to the investment theme.
Similar stocks to VolitionRX Ltd
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
